RIA
ABUS icon

Realta Investment Advisors’s Arbutus Biopharma ABUS Stock Holding History

Realta Investment Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11
Closed – – 301
2019
Q4 		$0 Hold
11
– – ﹤0.01% 1580
2019
Q3 		$0 Hold
11
– – ﹤0.01% 1601
2019
Q2 		$0 Hold
11
– – ﹤0.01% 1688
2019
Q1 		$0 Buy
+11
New +$42 ﹤0.01% 1324

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Realta Investment Advisors's ABUS Position: Q1 2020 in Review

Realta Investment Advisors sold out of Arbutus Biopharma (ABUS) in Q1 2020, closing a stake of 11 shares.

Realta Investment Advisors first reported a position in ABUS in Q1 2019 and held it in 4 quarters. The position peaked at $0 in Q4 2019. 48 funds tracked by Wall St. Rank hold ABUS as of Q1 2020.

  • Realta Investment Advisors reported no remaining Arbutus Biopharma position as of Q1 2020 after selling out during the quarter.
  • Realta Investment Advisors sold 11 Arbutus Biopharma shares in Q1 2020.
  • Realta Investment Advisors first reported a position in Arbutus Biopharma in Q1 2019 and held it in 4 quarters.
  • Realta Investment Advisors's Arbutus Biopharma position peaked at $0 in Q4 2019.
  • 48 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2020.

Based on Realta Investment Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.